Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
In brief
CAPLYTA’s Phase 3 success could pave the way for the first approved drug for acute manic episodes, enhancing JNJ’s neuropsychiatry pipeline.